, Singapore

Daily Markets Briefing: STI down 1.8%

Immediate resistance pegged at 3425 mark.

According to OCBC Investment Research:

The muted reactions on Wall Street last Friday night could continue to keep local sentiment cautious this morning, especially with US shut for a holiday tonight.

Recall that the STI made a sharp 1.8% retreat last Thursday, likely in response to the 7% plunge by the Nikkei 225 index on the same day.

While we could potentially see a technical rebound by the index this morning, concerns are likely to remain.

For now, the immediate resistance remains at 3425 minor support-turned-resistance; the next obstacle lies at the 3465 recent peak.

On the downside, the immediate support is now pegged at the 3383 level (Thursday’s intraday low), with the subsequent base at the 3320 key resistance-turned-support. 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare